Skip to main
VKTX

Viking Therapeutics (VKTX) Stock Forecast & Price Target

Viking Therapeutics (VKTX) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 50%
Buy 36%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Viking Therapeutics Inc is strategically enhancing its clinical updates and expanding its program pipeline, which includes promising products like VK2809, VK5211, and VK0214, contributing to an optimistic sentiment ahead of critical clinical readouts. The company's differentiation through VK2735 and an upcoming amylin agonist IND positions it favorably for lucrative partnerships and financing opportunities, supporting its advanced standing among independent late-stage metabolic players. Furthermore, Viking's maturity and robust data relative to peers allow it to leverage renewed investor interest, enhancing its potential for growth in a rapidly evolving market.

Bears say

Viking Therapeutics Inc. is subject to significant risks inherent in the biopharmaceutical industry, including the potential for unexpected outcomes from clinical trials and regulatory uncertainties that could impede progress. Additionally, the complexity of the commercial markets for its product candidates may further exacerbate the challenges it faces, particularly as pricing pressures increase. The heightened scrutiny of licensing deals, especially those involving US and China entities, adds an additional layer of concern regarding the company's ability to navigate its growth prospects effectively.

Viking Therapeutics (VKTX) has been analyzed by 14 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 36% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viking Therapeutics (VKTX) Forecast

Analysts have given Viking Therapeutics (VKTX) a Buy based on their latest research and market trends.

According to 14 analysts, Viking Therapeutics (VKTX) has a Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $87.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $87.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viking Therapeutics (VKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.